Life sciences

Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

Aging populations and chronic disease are putting pressure on health resources around the world just as scientific progress, augmented intelligence and digital data are transforming the traditional health care models. This is causing a power shift with new entrants (often not driven by profit) disrupting the incumbents.

Staying competitive and providing the personalized experience that patients demand require life sciences organizations to find new ways of working. Partnering with others to share data, medicine and resources while anticipating trends and regulatory changes will help ensure sustainability in the increasingly evidence-based, outcomes-focused sector.

We help companies across the biotechnology, pharmaceutical and medical technology fields harness this disruption by forming the right alliances, better allocating resources and building trust with customers.

Our latest thinking

How can you shape your IPO with confidence?

The EY Global IPO Trends Q3 2024 covers the news and insights on the global, area and regional IPO markets for Q3 and year-to-date 2024. Find out more.

George Chan

Pulse of the MedTech Industry Report

EY MedTech report on dealmaking, financing and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.

John Babitt + 1

EY Biotech Beyond Borders Report 2025

Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. Find out how.

The Unstoppables: Success stories of the world’s most inspiring entrepreneurs

The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.

Stasia Mitchell

How will you respond to clinicians sounding the alarm on unsustainable care delivery models?

The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.

How do you build future supply chains to best serve patient needs?

In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.

Derron Stark + 2

What going digital means for Takeda

Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.

Helmut Rattenberger + 1

How AI can support decision-making in drug development portfolios

For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.

Learn more (via ey.com US)

A female scientist in a lab

Close up of hand touching smartwatch with health app

Optimizing health outcomes for all

Discover key insights that highlight strategic priorities and investments to enhance care across sectors, along with the evolution of organizational capabilities, based on a survey of 500 industry leaders.

Read the report (via ey.com US)

Pharma promotional content management services

The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more
EY Smart Reviewer

The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more
Biopharma launch services

Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more
EY Health Outcomes Platform

The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more
Read more
Health and Wellness Strategy Consulting

Our Healthcare Strategy Consulting teams help organizations develop digital, transaction and value strategies to build resilience and drive future growth
Read more

Case studies

How a global biopharma became a leader in ethical AI

Read this case study about how a science-led biopharma positioned itself as a leader in ethical AI.

Catriona Campbell + 5

The team

Linda Hill

EY Global and Americas Consumer and Health Leader

Strategic leader focused on innovation. Collaborative team builder. Champion for audit quality. Client-centric problem solver. Avid reader. Ambitious hiker. Occasional middle school sports coach.

St. Louis, MO, United States

Daniel Mathews

EY Global Life Sciences Leader; EY EMEIA Life Sciences Market Lead

Passionate about driving health outcomes. Focused on making pharmaceutical innovations affordable and easily accessible to everyone.

London, United Kingdom

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.